⚖️Notice of Intent to Terminate Agricultural Marketing Service Scale Program
The U.S. Department of Agriculture's (USDA) Agricultural Marketing Service (AMS) proposes to terminate the master scale testing program effective September 30, 2025. Significantly reduced customer usage has led to insufficient collection of user fees that are required to cover program costs. AMS seeks public comment on this service termination from affected parties.
Learn More✈️User Fee Amendment for Agricultural Quarantine Inspection Services
On May 7, 2024, the Animal and Plant Health Inspection Service published in the Federal Register a final rule amending the user fee regulations associated with the agricultural quarantine and inspection (AQI) program. The final rule went into effect on October 1, 2024, with the exception of the removal of an exemption from paying the AQI user fee for commercial aircraft with 64 or fewer seats meeting certain conditions. The removal of the exemption would have taken effect on April 1, 2025. On March 21, 2025, we published a notice in the Federal Register delaying the effective date of the removal of the exemption from paying the AQI user fee for small commercial passenger aircraft, until June 2, 2025, and requesting information. As a result of the comments we received on that notice, we decided to delay implementation of the removal of the exemption indefinitely. However, as a result of an editorial error, the exemption had already been removed from the regulations. In this document, we are amending the regulations to restore the exemption from paying the AQI user fee for commercial aircraft with 64 or fewer seats meeting certain conditions.
Learn More💰FY 2026 Medical Device User Fees
The Food and Drug Administration (FDA) is announcing the fee rates and payment procedures for medical device user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Medical Device User Fee Amendments of 2022 (MDUFA V), authorizes FDA to collect user fees for certain medical device submissions and annual fees both for certain periodic reports and for establishments subject to registration. This notice establishes the fee rates for FY 2026, which apply from October 1, 2025, through September 30, 2026, and provides information on how the fees for FY 2026 were determined, the payment procedures you should follow, and how you may qualify for reduced small business fees.
Learn More💊New FDA Prescription Drug User Fee Rates for FY 2026
The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for prescription drug user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Prescription Drug User Fee Amendments of 2022 (PDUFA VII), authorizes FDA to collect application fees for certain applications for the review of human drug and biological products and prescription drug program fees for certain approved products. This notice establishes the fee rates for FY 2026.
Learn More💰FY 2026 Animal Generic Drug User Fee Rates and Procedures
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2026 generic new animal drug program user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Generic Drug User Fee Amendments of 2023 (AGDUFA IV), authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, for certain sponsors of such abbreviated applications for generic new animal drugs and/or investigational submissions for generic new animal drugs (JINADs), and for certain submissions related to JINAD files. This notice establishes the fee rates for FY 2026.
Learn More💰FDA Announces Animal Drug User Fee Rates for FY 2026
The Food and Drug Administration (FDA, the Agency, or we) is announcing the fee rates and payment procedures for fiscal year (FY) 2026 animal drug user fees. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Animal Drug User Fee Amendments of 2023 (ADUFA V), authorizes FDA to collect user fees for certain animal drug applications and supplemental animal drug applications, for certain animal drug products, for certain establishments where such products are made, and for certain sponsors of such animal drug applications and/or investigational animal drug submissions. This notice establishes the fee rates for FY 2026.
Learn More💵FDA Announces Biosimilar User Fee Rates for FY 2026
The Food and Drug Administration (FDA, Agency, or we) is announcing the rates for biosimilar user fees for fiscal year (FY) 2026. The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the Biosimilar User Fee Amendments of 2022 (BsUFA III), authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development; review of certain applications for approval of biosimilar biological products; and each biosimilar biological product approved in a biosimilar biological product application. BsUFA III directs FDA to establish, before the beginning of each fiscal year, the amount of initial and annual biosimilar biological product development (BPD) fees, the reactivation fee, and the biosimilar biological product application and program fees for such year.
Learn More💊FDA Announces User Fee Rates for Generic Drugs FY 2026
The Federal Food, Drug, and Cosmetic Act (FD&C Act or statute), as amended by the Generic Drug User Fee Amendments of 2022 (GDUFA III), authorizes the Food and Drug Administration (FDA, Agency, or we) to assess and collect fees for abbreviated new drug applications (ANDAs); drug master files (DMFs); generic drug active pharmaceutical ingredient (API) facilities, finished dosage form (FDF) facilities, and contract manufacturing organization (CMO) facilities; and generic drug applicant program user fees. In this document, FDA is announcing fiscal year (FY) 2026 rates for GDUFA III fees.
Learn More🏭FDA Notice on Tobacco Products User Fees and Data Submission Requirements
The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
Learn More💰Proposed Rule Change on Market Data Fees by Miami Exchange
The Miami International Securities Exchange has proposed amendments to its fee schedule for proprietary market data feeds, introducing new categories and pricing structures. The changes aim to align fees with those of affiliated exchanges while addressing subscription handling and ensuring equitable fee allocation to various users, including Professional and Non-Professional Users.
Learn More